J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

J INTS BIO South Korea California

View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-aacr-2024--jin-a02-a-novel-oral-4th-generation-egfr-tki-showing-clinical-benefits-in-the-ongoing-phase-1-study-302114160.html